Company: ARWR
Filing Date: 2025-10-10
Form Type: 10-K/A
Source: 0000879407-25-000013
Chunk: 37

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-10-10
Form: 10-K/A
Chunk 37
---
               — |     |    |     |                                   225,574 |     |    |     |                         — |     |           |    704,744 |
| Tracie Oliver (8)                             |     | 2024 |     | 484,065 |     |      — |     |       2,589,750 |     |    |     |                                         — |     |    |     |                     2,965 |     |           |  3,076,780 |
| Former Chief Commercial Officer               |     | 2023 |     | 647,261 |     |      — |     |          19,040 |     |    |     |                                   188,000 |     |    |     |                    19,521 |     |           |    873,822 |
|                                               |     | 2022 |     | 111,154 |     | 16,344 |     |       2,517,200 |     |    |     |                                    94,874 |     |    |     |                     4,899 |     |           |  2,744,471 |

(1) This column represents the total grant date fair value, computed in accordance with ASC 718, of RSUs granted during fiscal years 2024, 2023 and 2022. The assumptions used to calculate the value of the stock underlying the RSU awards are set forth in Note 9 of the Notes to the Consolidated Financial Statements included with the Company’s Annual Report on Form 10-K filed with the SEC on November 26, 2024 (the “Original Report”).

(2) These bonus amounts represent the amounts earned for performance under the Company’s Annual Bonus Incentive Plan during calendar years 2024, 2023 and 2022 and paid in fiscal years 2025, 2024 and 2023, respectively. The Annual Bonuses are described in more detail in the “Bonus Incentive” section.

(3) Amounts consist of 401(k) matching contribution, as well as life insurance premiums for the benefit of each executive officer.

(4) The amount reported for Christopher Anzalone in the Stock Awards column includes the grant date fair value of a fiscal 2024 RSU award that is subject to vesting upon the achievement of a specific performance condition. We determined the performance condition was 100% probable of being achieved as of the grant date, as defined under